Clinical Trial Update: Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study of CPI-613 (devimistat) with or without gemcitabine for metastatic pancreatic adenocarcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• Devimistat (CPI-613) (devimistat)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Cornerstone Pharmaceuticals | Conditions: Metastatic Pancreatic Adenocarcinoma | Phase 2 | Status: WITHDRAWN